Abiopharma

🔍 Naim Moises (Director)

Company: AES CORP (AES)

Report Date: 2026-04-29

Detailed Transactions and Holdings:

• Acquired 6,920 shares of Units (Derivative)
  Date: 2026-04-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 218,738.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F1, F1
• Acquired 12,111 shares of Units (Derivative)
  Date: 2026-04-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 230,849.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: Each stock unit is the economic equivalent of one share of AES Common Stock. These units will be settled for shares of AES Common Stock after the date the reporting person terminates service on the Board in accordance with the Director's election form under The AES Corporation 2025 Equity and Incentive Compensation Plan.
• F2: Represents cash fees that the reporting person elected to defer into stock units.
• REMARKS: Exhibit 24.1 Power of Attorney